Thor-707 sar444245
WebOct 29, 2024 · *THOR-707 (SAR444245) is a non-alpha IL-2 candidate with a best-in-class profile currently being evaluated in Phase 1 trials for the treatment of solid tumors PARIS … WebJun 6, 2024 · In early 2024, Sanofi bought small cancer biotech, Synthorx, which added the latter’s lead pipeline asset, THOR-707 (now SAR444245) to SNY’s immuno-oncology portfolio. SAR444245 is currently being evaluated in several mid-stage studies for treating various types of cancer indications.
Thor-707 sar444245
Did you know?
WebJun 3, 2024 · SAR444245 (formerly known as THOR-707), Sanofi’s product candidate, is a differentiated IL-2 engineered for specificity and selectivity towards CD8+ T cells and … WebCAR-targeted IL-2 Drives Selective CAR-T cell Expansion and Improves Anti-tumor Efficacy Nathan D. Mathewson1, Kelly D. Moynihan1, Sara Sleiman2, Wei Chen1, Paul Bessette1, Chris Kimberlin1,Danielle Pappas1, Terrence Park1, Eric Wigton1, Saar Gill2, Andy Yeung1, Ivana Djuretic1 1Asher Biotherapeutics, South San Francisco, CA; 2Division of Hematology …
WebA Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with advanced and metastatic gastrointestinal cancer (Pegasus Gastrointestinal 203) Studio di fase 2, non randomizzato, in aperto, ... WebA Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies …
WebApr 12, 2024 · 月9日，跨国制药巨头赛诺菲公布旗下工程化il-2药物thor-707（sar444245）中期临床阳性数据。 中期临床结果显示，与临床前数据一致， 患者在首次服用THOR-707后体内CD8+T细胞和NK细胞数量增加，并且整个给药周期内持续增加，具有剂量递增效应；与K药（pembrolizumab）联合使用时，这种效应更加明显。 WebImage for ESMO 2024: Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with …
WebJun 3, 2024 · In 2024, Sanofi presented interim, early-stage data on SAR444245 (previously THOR-707) as a monotherapy and in combination with an anti-PD-1 checkpoint inhibitor. The initial activity was observed, with three confirmed partial responses, including patients who had previous anti-PD-1 therapy.
WebA Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer. Analyze clinical trials with filters and metrics. Efficiently skim through many trials at a time. fifa world cup templateWebAug 9, 2024 · The THOR-707 volume of distribution at steady state (Vss; 82.4 mL/kg) was about 4.7-fold reduced relative to aldesleukin and similar to the blood volume for mice 17 … fifa world cup television broadcastersWebJun 27, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy … fifa world cup telecast time in indiaWeb去年，IL-2领域头部玩家Nektar的IL-2受体激动剂疗法Bempegaldesleukin的Ⅲ期临床失败令公司几近倒闭，包括之后赛诺菲的THOR-707单药活性不理想，放弃对SAR444245的Ⅱ期临床的继续推进，偏向性IL-2路线的应用前景也受到了广泛质疑。 griffon indoor sports complex softballWebNov 15, 2024 · SAR444245 (THOR-707) is a well differentiated and improved recombinant human interleukin-2 (IL-2) molecule that includes a PEG moiety irreversibly bound to a … griffon icebreakerWebOct 6, 2024 · Recently, Sanofi has developed a PEG-IL2 fusion, THOR-707 (SAR444245), that contains one permanent PEG chain located on a novel amino acid insertion. The location of the PEG chain blocks the ability of IL-2 to bind to IL-2R, generating a molecule biased towards CD8 T cells and NK cells expressing the IL-2R . griffon investor relationsWebOct 30, 2024 · Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA ® (pembrolizumab) in pursuit of establishing a new treatment option in oncology *THOR-707 (SAR444245) is a non-alpha IL-2 candidate with a best-in-class profile currently being evaluated in Phase 1 trials for the treatment of solid tumors griffon image mythologie